BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Rapamycin
,
rs3825942
,
MYC
,
T cell receptor signaling pathway
,
HIV infection
,
Pancreas
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
claudin 19
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Trigeminal ganglia
Dorsal root ganglia
Kidney medulla
Placenta
Kidney
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Hypomagnesemia
Low blood pressure
Kidney cancer
Pyloric ulcer
Alpha-1-antitrypsin deficiency
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
spliceostatin A
tazarotene
isoginkgetin
n-hexanal
SNCA protein, human
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
GDAP1
DDX17
SRSF1
SRSF1
CGAS
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Claudin-19 localizes to the thick ascending limb where its expression is required for junctional cla…
A Report of Claudin-19 Mutation Causing Nephrocalcinosis and End-Stage Kidney Disease from Iran.
Claudin 19 inhibits the malignant potential of breast cancer cells by modulating extracellular matri…
Congenital macular scars in siblings from CLDN19 mutations.
Heterogeneity is a common ground in familial hypomagnesemia with hypercalciuria and nephrocalcinosis…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)
Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor
Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Ca…
A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitab…
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatmen…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ